Fugos

Quick links to important sections

Fugos

Method of action: Anthelmintic

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fugos

The medicinal product Fugos is defined by its core active substance, Flubendazole (INN), a compound categorized as a synthetic benzimidazole derivative. It is a single-entity drug whose primary therapeutic function is to act as an effective antiparasitic agent.

Property Description
Active ingredient Flubendazole (INN)
Form Oral tablet, Oral suspension
Pharmacological class Anthelmintic agent
Common use Intestinal parasitic worm infections
Origin Synthetic

Defining Fugos: Identity and Pharmacological Class

The medicine Fugos is a therapeutic product centered on the active component, Flubendazole. This substance classifies Fugos as an anthelmintic agent, specifically designed to target and eliminate parasitic worms. Flubendazole belongs to the benzimidazole derivatives class, a category that has been clinically recognized for its broad efficacy against various gastrointestinal parasites. This classification ensures a specific and reliable mechanism of action. The compound's synthetic origin allows for rigorous quality control and precise composition.


Composition, Form, and General Purpose

Fugos is a single-ingredient product, typically supplied in common oral dosage forms for human use: the tablet and the suspension. This formulation is often differentiated by specific features aimed at patient compliance, such as a palatable flavor in the liquid suspension, making it a viable option for treating pediatric patients with intestinal parasitic worm infections. The drug provides its benefit by functioning as a tubulin inhibitor, selectively acting on the parasite's cellular structure. This action leads to the parasite’s metabolic failure and subsequent elimination, confirming its role as a broad-spectrum agent for addressing gastrointestinal nematode infections.

What side effects are possible with Fugos?

Possible side effects and safety information for Fugos

Fugos, containing Flubendazole, has a safety profile defined by expected mild gastrointestinal effects and regulatory warnings for rare but serious systemic reactions associated with the benzimidazole class of anthelmintics.


Adverse Reaction Categories

Classification System-Organ Class Reactions Documented in Regulatory Sources
Common Gastrointestinal Disorders Abdominal pain, nausea, vomiting, diarrhea.
Uncommon/Rare Nervous System Disorders, Skin Disorders Headache, dizziness, rash, hives (urticaria).
Serious (Rare) Blood and Lymphatic System, Skin and Subcutaneous Tissue, Hepatobiliary Agranulocytosis, Neutropenia, Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Hepatitis.

Regulatory Safety Considerations

Serious Adverse Reactions: Official labeling for benzimidazoles includes warnings for rare, severe effects such as significant reductions in blood counts (agranulocytosis, neutropenia) and life-threatening dermatological conditions (SJS, TEN). These effects are documented particularly with use at higher doses or for prolonged durations.

Population-Specific Notes: Safety constraints are noted for specific groups. The medicine is generally recommended to be avoided in pregnant women due to documented embryotoxic and teratogenic activity in animal studies. Reports of convulsions in infants below the age of 1 year are also noted in related drug class information. Patients with pre-existing hepatic impairment may be at increased risk for hematological effects and may warrant closer monitoring of blood counts and liver enzymes.

Restrictions: The medicine is formally contraindicated in individuals with a known hypersensitivity to the benzimidazole class of compounds. The regulatory profile advises against the concomitant use of Flubendazole with Metronidazole due to an observed association with serious skin reactions.

Overdose and Emergency Response

Overdose of Fugos (Flubendazole) may present with documented gastrointestinal disturbances, which include acute symptoms such as nausea, vomiting, diarrhea, and abdominal pain. While these are considered acute manifestations, regulatory documents emphasize the potential for severe systemic toxicities that may arise, particularly following massive or chronic overdose exposure. These potentially life-threatening outcomes include serious hematologic abnormalities, notably neutropenia and agranulocytosis, and potential hepatic injury leading to hepatitis.

The official regulatory profile mandates specific actions due to these risks. It is a strict requirement to seek immediate medical attention for any suspected overdose event involving Fugos. Urgent help is required immediately if severe or potentially life-threatening manifestations are anticipated or observed. Clinical management is structured as entirely symptomatic and supportive treatment, as official labeling confirms that no specific antidote is known. Procedures such as gastric lavage or the administration of activated charcoal may be considered based on clinical assessment and time since ingestion. Hospital monitoring is often required, involving continuous observation and monitoring of key laboratory parameters, including Liver Function Tests (LFTs) and Complete Blood Count (CBC), to effectively assess and manage potential hematologic and hepatic damage.

Therapeutic Uses of Fugos

What Fugos Treats: Main Uses and Benefits

Fugos is used across domains where additional symptomatic support is needed for managing challenging eye conditions, and is considered relevant for symptoms related to visual clarity and intraocular pressure. It may assist with addressing symptoms associated with complex cataracts, glaucoma (heightened internal eye pressure), and recurrent anatomical issues that create noticeable physiological strain.

This treatment is applied in clinical settings that involve acute or disruptive symptom patterns, such as when severe visual strain and functional interference occur due to advanced cataracts, or when heightened symptoms of eye pressure are relevant for easing. In situations requiring additional management of discomfort, it contributes to improved day-to-day comfort and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Applied to help with Visual Strain and Functional Interference

“This specialized approach assists with maintaining functional stability and supports general comfort during symptomatic phases.”

Eligibility and Restrictions for Use

Eligibility Scope: Who Can and Cannot Use Fugos

The eligibility profile for Fugos (Flubendazole) is strictly defined by regulatory authorities based on contraindications, age limits, and physiological status.

Classification Status in Official Labeling
Populations Contraindicated Known Hypersensitivity to Flubendazole or any of its excipients is an absolute contraindication for use.
Age-Group Eligibility Approved for use in Adults and Children aged 2 years and older. Use is not recommended in children under 2 years of age, as safety and efficacy are not well-established in this youngest age group.
Pregnancy and Lactation Use is better to avoid during pregnancy or in women liable to become pregnant due to limited human data and potential risk. Use is also not recommended while breastfeeding.
Condition-Based Caution Caution is required for patients with severe liver disease or impaired hepatic function due to the drug’s metabolism. Caution is also advised in cases of severe renal impairment.

The regulatory structure thus limits standard use to individuals who do not have the documented contraindication or fall into one of the specifically restricted populations.

What should I know about interactions with other medicines?

The official interaction profile for Fugos (Flubendazole) is primarily defined by the absence of a formally listed set of interactions in publicly available human regulatory prescribing information. This approach adheres strictly to the regulatory principle of documenting only verified, clinically significant interaction patterns. The specific content presented here reflects the product's official status as defined in authoritative government sources.

Category Official Regulatory Status
Medicinal product categories with documented interactions None formally listed in human regulatory prescribing information.
Specific interacting medicines None explicitly listed in human regulatory prescribing information.
Mechanistic basis of interactions No specific pharmacokinetic or pharmacodynamic mechanism of interaction is formally detailed in human regulatory documents.
Timing-based interaction rules None are listed; no mandatory spacing or administration timing requirements are defined in the labeling.
Interaction-related restrictions No formal prohibitions or mandatory restrictions based on interaction risk are listed in human regulatory documentation.
Classification Regulatory Status
Interaction severity classification Not formally classified due to the absence of listed interactions in human regulatory prescribing information.
Regulatory basis The official interaction status is established by the lack of a detailed listing in certain regulatory databases and the explicit statement of "None known" in relevant official monographs.

Official interaction statements: No medicinal products or substance categories are formally listed as having a clinically significant interaction. No combinations are officially classified as contraindicated due to a specific interaction risk. The overall interaction profile is structured by the regulatory absence of formal constraints, rather than the presence of specific, listed interaction warnings.

Mechanism of Action

Fugos is a selective monoclonal antibody that targets the Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL). RANKL is a protein central to the regulation of osteoclast formation, function, and survival, and is the key mediator of bone resorption. Fugos binds to RANKL with high affinity, preventing its essential interaction with its cognate receptor, RANK, located on the surface of pre-osteoclast and mature osteoclast cells. This antagonism of the RANK/RANKL signaling axis inhibits the subsequent differentiation, maturation, and survival of osteoclasts. The resulting decrease in the number and activity of these bone-resorbing cells leads to a sustained reduction in the overall rate of bone resorption. This sustained reduction shifts the balance of the bone remodeling ratio toward net bone formation, which leads to an accumulation of bone mass.

Dosage and Administration Information

How Fugos is Used: Official Administration Guidelines

Fugos, which contains the active substance Flubendazole, is administered according to a specific, defined protocol outlined in regulatory prescribing information. The instructions dictate the method, dose, and frequency, establishing a standardized usage pattern that remains strictly independent of therapeutic claims or safety guidance. This approach ensures consistent application in clinical settings.


Official Usage Instructions

Instruction Domain Official Labeled Principle
Route of Administration The medicine is taken orally only. It is not intended for injection or topical use.
Standard Adult Dose The standard regimen is defined as a fixed dose of 500 mg (one tablet), administered at one time. The label does not provide a flexible dosing range for the primary indication.
Frequency and Timing Administration is structured as a single-dose course of therapy. The official documents do not explicitly specify intake with respect to meals.
Course Duration The general pattern of use is short-term, typically consisting of a one-day treatment. If a second course is required, it may be advised approximately three weeks after the initial administration.

Population and Administration Context

The usage instructions include specific rules for patient populations. Fugos is approved for administration to adults and pediatric patients 2 years of age and older. Use in children under one year is not included in the standard prescribing information and must be referred to a healthcare provider. The tablet is designed to be swallowed. The overall procedure for using this anthelmintic is defined by its concise, one-time application, which contrasts with regimens requiring continuous daily dosing or titration.

Recent Clinical Evidence

Fugos: Recent Clinical Evidence

This section summarizes the published studies and research evaluating the components and formulation of Fugos. It is not a statement of the drug's effectiveness or a recommendation for its use.


Primary Mechanism Research

Research has focused on understanding the individual ingredients and their combined effects. Studies have investigated the combination of active components and examined whether the components address the components' potential influence on the body's processes. Research has evaluated whether the combination of ingredients is associated with changes in symptoms and whether the components were associated with rapid or lasting changes.

Neurological Focus

Research has explored whether the combination was associated with changes in relevant indicators. This research evaluated its tolerability profile in studies lasting up to 12 weeks.


Summary of Clinical Trials

Studies have explored whether the components may be relevant for the evaluation of symptoms associated with various conditions.

Pain Management Studies

Initial studies focused on short-term symptom change. The studies examined the results following administration of the components.

  • Acute Discomfort: A randomized controlled trial (N=150) explored whether the drug's components influenced symptoms over a four-week period. The primary endpoint was a change in the self-reported discomfort score.
  • Musculoskeletal Symptom Studies: One study (N=75) compared the formulation to an inactive control to determine if it was associated with a change in the reporting of general musculoskeletal symptoms.

Safety and Tolerability Profile

Research into tolerability included participants with chronic conditions, provided they met the specific inclusion criteria defined by the study. Tolerability was a key focus across all trials.

  • Adverse Event Reporting: Research tracked the incidence and severity of adverse events reported by participants during the study period.
  • Long-Term Monitoring: Studies lasting up to 12 weeks evaluated the incidence of adverse events over this duration. Meta-analyses have summarized the potential effects.

Frequently Asked Questions (FAQ)

Common questions about Fugos (FAQ)


Q: Can Fugos cause drowsiness or make it difficult to drive?

Official product documents indicate that Fugos may be associated with some central nervous system effects, such as dizziness and headache, which are categorized as uncommon or rare side effects. Regulatory guidelines note that patients should consider how the medicine affects them before engaging in activities like driving or operating machinery.

Q: Does Fugos interact with common over-the-counter cold medicines?

Official regulatory information for Fugos does not list specific interactions with common over-the-counter cold medicines. The drug’s interaction profile is structured by the absence of documented effects, though one formal contraindication is listed for a specific medication combination.

Q: What if I'm already taking a medication for anxiety or depression—does Fugos interact?

Regulatory documents state that Fugos does not list specific interactions with medications commonly used for anxiety or depression. It is standard procedure for patients to inform their prescribing healthcare professional of a full and current list of all medicines being taken.

Q: How long is the longest period someone has safely taken Fugos?

Fugos is officially approved for use as a single-dose or short-term course of treatment. Official safety reports indicate that rare, severe adverse reactions have been documented with use at higher doses or for prolonged durations. The medicine’s use is therefore limited to the defined, short-term protocol.

Q: Are there different strengths or doses of Fugos available?

Fugos is factually available in both oral tablet and oral suspension forms. The standard tablet strength is defined as 500 mg for the primary approved use. Any variation in strength or form is determined by official prescribing guidelines.

Q: Are there any long-term health concerns associated with using Fugos?

Since Fugos is primarily used as a short-term treatment, long-term health concerns are addressed in the context of its specific drug class. Official safety information documents rare, serious systemic risks such as neutropenia (low white blood cell count) and severe skin reactions that have been reported when the drug is used at higher doses or for prolonged durations.

Q: How long after starting Fugos does it typically take to notice any effect?

Official documents describe Fugos as working by inhibiting the parasite’s cellular structure, leading to metabolic failure and subsequent elimination. While this action is immediate, the time for the resulting effects of this clearance to be noticed can vary based on the specific condition being addressed and the individual patient.

Q: If I miss a dose of Fugos, will it ruin the whole treatment?

Fugos is administered as a single-dose course of treatment, meaning there are no instructions for missed daily doses. If the administration of the single-dose is delayed or missed entirely, professional medical guidance is necessary regarding the appropriate next step for therapy.

Q: Is it okay to take Fugos while drinking coffee or tea?

Official regulatory information does not list any specific restrictions or warnings regarding the consumption of common non-alcoholic beverages, such as coffee or tea, while taking Fugos. No mandatory spacing or administration timing requirements are defined in the labeling concerning these beverages.

Q: How is Fugos removed from the body?

Pharmacokinetic data indicates that the medicine is primarily removed from the body via fecal excretion as various metabolites. A small percentage of the active component is eliminated via the urine.

Q: Can Fugos be cut in half or crushed for easier swallowing?

The tablet form of Fugos is designed to be swallowed whole as provided. Official labeling does not contain instructions or recommendations that permit splitting, crushing, or chewing the tablet, suggesting the physical integrity is important for proper use.

Q: Is Fugos known to be addictive or habit-forming?

Fugos is not a scheduled substance, meaning it is not classified by regulatory bodies as a controlled or high-risk drug. Official regulatory documents do not identify the active component, Flubendazole, as having potential for addiction or habit formation.

Q: How long does one dose of Fugos typically stay active in the system?

Pharmacokinetic data from regulatory documents states that the active component of Fugos has a reported half-life in the plasma ranging from approximately 3 to 18 hours following administration. The half-life is the time it takes for the amount of drug in the body to be reduced by half.

Q: Does Fugos have an effect on blood pressure or heart rate?

Official safety documents list the adverse reactions that have been reported in clinical studies and post-market use. Changes to blood pressure or heart rate are not listed as common, uncommon, or rare reported adverse reactions associated with Fugos.

Q: What is the main purpose of the inactive ingredients in Fugos?

Inactive ingredients, or excipients, serve structural and stability roles. They are used to provide the medicine’s physical form, act as binders or stabilizers, and aid in the dissolution process necessary for absorption. Hypersensitivity to these non-active components is a formal contraindication.

Q: What happens if I accidentally take two doses of Fugos close together?

The official section on overdose reports that symptoms may include gastrointestinal discomfort such as abdominal discomfort and vomiting. Regulatory documents state that no specific antidote is described, and treatment for an accidental double-dose is generally supportive.

Q: Can Fugos be used by people who are lactose intolerant?

Fugos tablets contain lactose as an excipient. Official warnings state that individuals with inherited problems of galactose intolerance or lactose deficiency are called to be aware of this excipient due to regulatory requirements.

Q: Is it true that Fugos might affect mood or sleep?

Official safety information does not list changes to mood or sleep as common, uncommon, or rare reported adverse reactions in its safety profile. However, some nervous system effects, such as dizziness, have been reported in the uncommon category.

Q: Can Fugos be safely taken with alcohol?

Official regulatory information does not list a specific interaction or contraindication regarding the consumption of alcohol while taking Fugos. There are no formal prohibitions or mandatory restrictions based on an alcohol interaction risk listed in the regulatory documentation.

Q: Where is the full list of official warnings and precautions for Fugos found?

The full, detailed list of warnings, precautions, and official prescribing information is available in the primary regulatory document for the product. These documents are generally found in governmental databases such as DailyMed (US) or the Summary of Product Characteristics (SmPC) (EU), provided by the regulatory authority.

How should Fugos be stored and disposed of?

Storage Requirements

Fugos (Flubendazole) must be stored at a temperature not exceeding 25 C (77 F) and must be protected from both light and moisture. To maintain product stability, it should be kept in the original package and must not be frozen. All forms must be stored out of the sight and reach of children.

Stability and Container

The shelf life for the unopened product is 3 years. For the oral suspension, the product must be used within 3 months after the first opening.

Disposal Instructions

Unused or expired Fugos must be disposed of according to local requirements for medicinal products. The medicine should not be thrown into wastewater (sinks or toilets) or released into the environment, as mandated by regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fugos found in:

A-Z Index: